CHICAGO, IL / ACCESS Newswire / December 19, 2025 / For a long stretch, Cosmos Health (NASDAQ:COSM) sat in a familiar category. A company investors respected, followed, and occasionally revisited, but rarely rushed toward. It had moving parts, a broad footprint, and a strategy that required patience. That approach can work, but healthcare investors tend to reward momentum. Cosmos recognized that reality and adjusted accordingly.

The result was not a cosmetic shift. It was a recalibration of focus that allowed the rest of the story to start falling into place. Better still, it produced results. In its most recent quarter, Cosmos Health reported revenue north of $17 million, the highest in the company's history.

That figure does more than mark a record. It reframes the discussion around who Cosmos is today, what the company is executing on, and where it is realistically headed next.

Revenue Growth Is No Longer Abstract

The headline revenue number drew attention, but it is only part of the picture. What gives the quarter real weight is what sits beneath it. Gross profit margins expanded meaningfully alongside revenue growth, reinforcing that scale is starting to work in Cosmos Health's favor.

That dynamic carries two implications. First, more revenue translates into economic contribution. Second, the company is approaching the type of operating inflection investors watch for in diversified healthcare models. This is not a single-asset business, and that context matters.

Cosmos Health operates across pharmaceuticals, nutraceuticals and healthcare services. That breadth is intentional. It allows the company to respond to shifts in demand, pricing pressure, and regional market dynamics without becoming overly dependent on any single product line. As revenue grows, that flexibility becomes an advantage rather than a complication.

Operational discipline is also showing up where it should. Manufacturing capabilities that comply with European GMP standards and established distribution infrastructure give Cosmos tighter control over cost, quality, and execution. The result is a business that is not just growing, but learning how to convert growth into durability.

Revenue without margin is noise. Revenue accompanied by an improving margin is progress.

When a Platform Starts to Behave Like One

The quarter also helps clarify something investors have been tracking quietly for some time. Cosmos Health is not assembling assets simply to get bigger. It is assembling the right pieces to scale responsibly and create shareholder value.

The integration of healthcare services, including the ZipDoctor & Cloudscreen acquisitions, expands the company's reach beyond products alone. It brings Cosmos Health closer to the patient, introduces recurring engagement, and adds a services layer that complements its physical product portfolio.

Alongside that operating progress, recent capital actions reinforce management's alignment with the business. CEO Greg Siokas has continued to accumulate company shares through continued purchases, signaling confidence grounded in execution rather than commentary. Cosmos Health has also made incremental additions to its diversified balance-sheet framework, including a recently disclosed $500,000 purchase of Ethereum under its existing digital assets facility. Total investment now reaches over $2 million under that $300 million facility.

The takeaway is straightforward. Cosmos Health is no longer defined by what it plans to build. It is increasingly defined by what it is already delivering. Revenue is scaling. Margins are responding. The platform is starting to perform where it matters most, in the market. That combination may not guarantee outcomes, but it does establish credibility. And in healthcare, credibility is the currency that ultimately determines who gets to grow.

If so, recent performance may be an early indicator of how disciplined execution can begin to compound.

About Cosmos Health Inc.

Cosmos Health Inc. (NASDAQ: COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept®, and C-Scrub®.

Through its subsidiary Cana Laboratories S.A., which is licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), Cosmos Health manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. The company also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and over-the-counter medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the United Kingdom.

Cosmos Health has established research and development partnerships targeting major health disorders such as obesity, diabetes, and cancer, supported by artificial intelligence-driven drug repurposing technologies. The company focuses on the development of novel patented and repurposed drugs through the AI platform Cloudscreen, nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. In addition, Cosmos Health has expanded into telehealth through the acquisition of ZipDoctor, Inc., based in Texas.

With a global distribution platform, the company is currently expanding throughout Europe, Asia, and North America, and maintains offices and distribution centers in Thessaloniki and Athens, Greece, as well as Harlow, United Kingdom. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, and www.cloudscreen.gr, as well as on LinkedIn and X.

Forward-Looking Statements

With the exception of the historical information contained herein, this communication may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans," and similar expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could," generally identify forward-looking statements, although not all forward-looking statements contain these words.

These statements involve risks and uncertainties that may materially affect the matters discussed herein for reasons outside the company's control, including, but not limited to, the company's ability to raise sufficient financing to implement its business plan, the effectiveness of its digital asset strategies, including accumulation and yield-generating activities, the impact of the war in Ukraine on the company's business and operations, and the company's ability to successfully develop and commercialize its proprietary products and technologies.

Readers are cautioned not to place undue reliance on forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the company's filings with the U.S. Securities and Exchange Commission, available at www.sec.gov. The company disclaims any obligation to update or revise forward-looking statements, whether as a result of new information, future events, or otherwise.

Contact for this content: info@hawkpointmedia.com

SOURCE: Hawk Point Media